TY - JOUR TI - Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA2LEN) survey AU - Makowska, J.S. AU - Burney, P. AU - Jarvis, D. AU - Keil, T. AU - Tomassen, P. AU - Bislimovska, J. AU - Brozek, G. AU - Bachert, C. AU - Baelum, J. AU - Bindslev-Jensen, C. AU - Bousquet, J. AU - Bousquet, P.J. AU - Kai-Håkon, C. AU - Dahlen, S.E. AU - Dahlen, B. AU - Fokkens, W.J. AU - Forsberg, B. AU - Gjomarkaj, M. AU - Howarth, P. AU - Salagean, E. AU - Janson, C. AU - Kasper, L. AU - Kraemer, U. AU - Louiro, C. AU - Lundback, B. AU - Minov, J. AU - Nizankowska-Mogilnicka, E. AU - Papadopoulos, N. AU - Sakellariou, A.G. AU - Todo-Bom, A. AU - Toskala, E. AU - Zejda, J.E. AU - Zuberbier, T. AU - Kowalski, M.L. JO - Allergy: European Journal of Allergy and Clinical Immunology PY - 2016 VL - 71 TODO - 11 SP - 1603-1611 PB - Wiley-Blackwell Publishing Ltd SN - null TODO - 10.1111/all.12941 TODO - nonsteroid antiinflammatory agent; nonsteroid antiinflammatory agent, adolescent; adult; age; aged; allergic rhinitis; Article; asthma; chronic rhinosinusitis; clinical assessment; comorbidity; confidence interval; correlation analysis; cross-sectional study; dyspnea; environmental factor; Europe; female; gender; Germany; Greece; health survey; hospitalization; human; lower respiratory tract; major clinical study; male; medical history; middle aged; multicenter study; multivariate analysis; Norway; odds ratio; population research; prevalence; priority journal; questionnaire; respiratory tract allergy; respiratory tract disease; smoking; statistical analysis; upper respiratory tract; drug hypersensitivity; health survey; respiratory tract allergy; risk factor; young adult, Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Cross-Sectional Studies; Drug Hypersensitivity; Europe; Female; Humans; Male; Middle Aged; Odds Ratio; Population Surveillance; Prevalence; Respiratory Hypersensitivity; Risk Factors; Young Adult TODO - Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAID-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders. Methods: The GA2LEN survey was conducted in 22 centers in 15 European countries. Each of 19 centers selected random samples of 5000 adults aged 15–74 from their general population, and in three centers (Athens, Munich, Oslo), a younger population was sampled. Questionnaires including questions about age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by mail. Totally, 62 737 participants completed the questionnaires. Results: The mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish centers [Katowice (4.9%), Krakow (4.8%), and Lodz (4.4%)] and lowest in Skopje, (0.9%), Amsterdam (1.1%), and Umea (1.2%). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI 1.78–2.74), asthma symptoms in last 12 months (2.7; 2.18–3.35), hospitalization due to asthma (1.53; 1.22–1.99), and adults vs children (1.53; 1.24–1.89), but was not associated with allergic rhinitis. Conclusion: Our study documented significant variation between European countries in the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ER -